Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Running, not enrolling · Phase 3

Conditions studied: Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors

In brief

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Key facts

Study ID

NCT05059522

Run by

Pfizer

People needed

77

Starts

2021-09-29

Expected to finish

2026-12-31

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.
• Participants must agree to follow the reproductive criteria.
• Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.

You may not qualify if…

• Female participants who are pregnant or breastfeeding.
• Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Where it is running

• Highlands Oncology Group, PA — Rogers, Arkansas, United States
• Highlands Oncology Group, PA — Springdale, Arkansas, United States
• The Regents of the University of California — Los Angeles, California, United States
• UCLA Hematology/Oncology — Los Angeles, California, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• MSK Basking Ridge — Basking Ridge, New Jersey, United States
• MSK Monmouth — Middletown, New Jersey, United States
• MSK Bergen — Montvale, New Jersey, United States
• MSK Commack — Commack, New York, United States
• MSK Westchester — Harrison, New York, United States
• Memorial Sloan Kettering Cancer Center (IDS Pharmacy) — Long Island City, New York, United States
• Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street). — New York, New York, United States
• Memorial Sloan Kettering Cancer Center 53rd street. — New York, New York, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• MSK Nassau — Uniondale, New York, United States
• Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
• The Trustees of the University of Pennsylvania, Clinical Research (OCR) — Philadelphia, Pennsylvania, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
• Fred Hutchinson Cancer Center — Seattle, Washington, United States
• Macquarie University — North Ryde, New South Wales, Australia
• Mater Hospital Sydney — Wollstonecraft, New South Wales, Australia
• Melanoma Institute Australia — Wollstonecraft, New South Wales, Australia
• The Prince Charles Hospital — Chermside, Queensland, Australia
• UZ Gent — Ghent, Oost-vlaanderen, Belgium
• Highlands Oncology Group, PA — Fayetteville, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.